Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.57 |
| ▸ | MEN1 | O00255 | 6/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | KLK7 | P49862 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10175701 | 0.93 | KMT2A (0.62) | KMT2AMEN1POLBSMN1; SMN2LMNA | |
| SCHEMBL10175698 | 0.87 | KDM4E (0.67) | KMT2AMEN1POLBSMN1; SMN2LMNA | |
| SCHEMBL10175700 | 0.87 | KMT2A (0.58) | KMT2AMEN1POLBLMNASCN3A | |
| SCHEMBL10175705 | 0.87 | MEN1 (0.67) | KMT2AMEN1LMNAALDH1A1GAA | |
| SCHEMBL29768452 | 0.86 | POLB (0.76) | KMT2AMEN1POLBSMN1; SMN2LMNA | |
| SCHEMBL10175711 | 0.86 | LMNA (0.71) | KMT2AMEN1POLBLMNASCN3A | |
| SCHEMBL2610070 | 0.86 | LMNA (0.66) | KMT2AMEN1SMN1; SMN2LMNASCN3A | |
| SCHEMBL2610073 | 0.85 | KMT2A (0.72) | KMT2AMEN1POLBRXFP1L3MBTL1 | |
| SCHEMBL10175988 | 0.85 | KMT2A (0.72) | KMT2AMEN1POLBRXFP1L3MBTL1 | |
| SCHEMBL10175696 | 0.85 | KMT2A (0.63) | KMT2AMEN1POLBLMNARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150099781-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-09 | — | — | US | disclosed |
| US-8969342-B2 | Compounds and methods for treating mammalian gastrointestinal microbial infections | BRANDEIS UNIVERSITY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20120101096-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | University of Georgia Foundation, Inc. (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101096-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | IMPDH1, IMPDH2, IMPA1 | KMT2A 3016/4885MEN1 3561/4885POLB 2033/4885 |
| US-20150099781-A1 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections | IMPDH1, IMPDH2, IMPA1 | KMT2A 3016/4885MEN1 3561/4885POLB 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.